{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T02:40:12Z","timestamp":1791081612187,"version":"4.1.0"},"reference-count":15,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2009,4,10]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p> Azacitidine (AZA) is effective treatment for myelodysplastic syndromes (MDS) at a dosing schedule of 75 mg\/m<jats:sup>2<\/jats:sup>\/d subcutaneously for 7 days every 4 weeks. The initial phase of this ongoing multicenter, community-based, open-label study evaluated three alternative AZA dosing schedules without weekend dosing. <\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p> MDS patients were randomly assigned to one of three regimens every 4 weeks for six cycles: AZA 5-2-2 (75 mg\/m<jats:sup>2<\/jats:sup>\/d subcutaneously for 5 days, followed by 2 days no treatment, then 75 mg\/m<jats:sup>2<\/jats:sup>\/d for 2 days); AZA 5-2-5 (50 mg\/m<jats:sup>2<\/jats:sup>\/d subcutaneously for 5 days, followed by 2 days no treatment, then 50 mg\/m<jats:sup>2<\/jats:sup>\/d for 5 days); or AZA 5 (75 mg\/m<jats:sup>2<\/jats:sup>\/d subcutaneously for 5 days). <\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p> Of patients randomly assigned to AZA 5-2-2 (n = 50), AZA 5-2-5 (n = 51), or AZA 5 (n = 50), most were French-American-British (FAB) lower risk (refractory anemia [RA]\/RA with ringed sideroblasts\/chronic myelomonocytic leukemia with &lt; 5% bone marrow blasts, 63%) or RA with excess blasts (30%), and 79 (52%) completed \u2265 six treatment cycles. Hematologic improvement (HI) was achieved by 44% (22 of 50), 45% (23 of 51), and 56% (28 of 50) of AZA 5-2-2, AZA 5-2-5, and AZA 5 arms, respectively. Proportions of RBC transfusion\u2013dependent patients who achieved transfusion independence were 50% (12 of 24), 55% (12 of 22), and 64% (16 of 25), and of FAB lower-risk transfusion-dependent patients were 53% (nine of 17), 50% (six of 12), and 61% (11 of 18), respectively. In the AZA 5-2-2, AZA 5-2-5, and AZA 5 groups, 84%, 77%, and 58%, respectively, experienced \u2265 1 grade 3 to 4 adverse events. <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p> All three alternative dosing regimens produced HI, RBC transfusion independence, and safety responses consistent with the currently approved AZA regimen. These results support AZA benefits in transfusion-dependent lower-risk MDS patients. <\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.2008.17.1058","type":"journal-article","created":{"date-parts":[[2009,3,3]],"date-time":"2009-03-03T02:11:18Z","timestamp":1236046278000},"page":"1850-1856","source":"Crossref","is-referenced-by-count":236,"title":["Hematologic Response to Three Alternative Dosing Schedules of Azacitidine in Patients With Myelodysplastic Syndromes"],"prefix":"10.1200","volume":"27","author":[{"given":"Roger M.","family":"Lyons","sequence":"first","affiliation":[{"name":"From the Cancer Care Centers of South Texas and US Oncology, San Antonio and Houston, TX; Hematology & Oncology Specialists, LLC, New Orleans, LA; Joliet Oncology Hematology Associates, Joliet, IL; Cancer Care Northwest, Spokane, WA; The Sarah Cannon Research Institute, Nashville, TN; Rocky Mountain Cancer Centers, LLP, Denver, CO; and Celgene Corporation, Overland Park, KS."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M.","family":"Cosgriff","sequence":"additional","affiliation":[{"name":"From the Cancer Care Centers of South Texas and US Oncology, San Antonio and Houston, TX; Hematology & Oncology Specialists, LLC, New Orleans, LA; Joliet Oncology Hematology Associates, Joliet, IL; Cancer Care Northwest, Spokane, WA; The Sarah Cannon Research Institute, Nashville, TN; Rocky Mountain Cancer Centers, LLP, Denver, CO; and Celgene Corporation, Overland Park, KS."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjiv S.","family":"Modi","sequence":"additional","affiliation":[{"name":"From the Cancer Care Centers of South Texas and US Oncology, San Antonio and Houston, TX; Hematology & Oncology Specialists, LLC, New Orleans, LA; Joliet Oncology Hematology Associates, Joliet, IL; Cancer Care Northwest, Spokane, WA; The Sarah Cannon Research Institute, Nashville, TN; Rocky Mountain Cancer Centers, LLP, Denver, CO; and Celgene Corporation, Overland Park, KS."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert H.","family":"Gersh","sequence":"additional","affiliation":[{"name":"From the Cancer Care Centers of South Texas and US Oncology, San Antonio and Houston, TX; Hematology & Oncology Specialists, LLC, New Orleans, LA; Joliet Oncology Hematology Associates, Joliet, IL; Cancer Care Northwest, Spokane, WA; The Sarah Cannon Research Institute, Nashville, TN; Rocky Mountain Cancer Centers, LLP, Denver, CO; and Celgene Corporation, Overland Park, KS."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Hainsworth","sequence":"additional","affiliation":[{"name":"From the Cancer Care Centers of South Texas and US Oncology, San Antonio and Houston, TX; Hematology & Oncology Specialists, LLC, New Orleans, LA; Joliet Oncology Hematology Associates, Joliet, IL; Cancer Care Northwest, Spokane, WA; The Sarah Cannon Research Institute, Nashville, TN; Rocky Mountain Cancer Centers, LLP, Denver, CO; and Celgene Corporation, Overland Park, KS."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allen L.","family":"Cohn","sequence":"additional","affiliation":[{"name":"From the Cancer Care Centers of South Texas and US Oncology, San Antonio and Houston, TX; Hematology & Oncology Specialists, LLC, New Orleans, LA; Joliet Oncology Hematology Associates, Joliet, IL; Cancer Care Northwest, Spokane, WA; The Sarah Cannon Research Institute, Nashville, TN; Rocky Mountain Cancer Centers, LLP, Denver, CO; and Celgene Corporation, Overland Park, KS."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi J.","family":"McIntyre","sequence":"additional","affiliation":[{"name":"From the Cancer Care Centers of South Texas and US Oncology, San Antonio and Houston, TX; Hematology & Oncology Specialists, LLC, New Orleans, LA; Joliet Oncology Hematology Associates, Joliet, IL; Cancer Care Northwest, Spokane, WA; The Sarah Cannon Research Institute, Nashville, TN; Rocky Mountain Cancer Centers, LLP, Denver, CO; and Celgene Corporation, Overland Park, KS."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Indra J.","family":"Fernando","sequence":"additional","affiliation":[{"name":"From the Cancer Care Centers of South Texas and US Oncology, San Antonio and Houston, TX; Hematology & Oncology Specialists, LLC, New Orleans, LA; Joliet Oncology Hematology Associates, Joliet, IL; Cancer Care Northwest, Spokane, WA; The Sarah Cannon Research Institute, Nashville, TN; Rocky Mountain Cancer Centers, LLP, Denver, CO; and Celgene Corporation, Overland Park, KS."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay T.","family":"Backstrom","sequence":"additional","affiliation":[{"name":"From the Cancer Care Centers of South Texas and US Oncology, San Antonio and Houston, TX; Hematology & Oncology Specialists, LLC, New Orleans, LA; Joliet Oncology Hematology Associates, Joliet, IL; Cancer Care Northwest, Spokane, WA; The Sarah Cannon Research Institute, Nashville, TN; Rocky Mountain Cancer Centers, LLP, Denver, CO; and Celgene Corporation, Overland Park, KS."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.L.","family":"Beach","sequence":"additional","affiliation":[{"name":"From the Cancer Care Centers of South Texas and US Oncology, San Antonio and Houston, TX; Hematology & Oncology Specialists, LLC, New Orleans, LA; Joliet Oncology Hematology Associates, Joliet, IL; Cancer Care Northwest, Spokane, WA; The Sarah Cannon Research Institute, Nashville, TN; Rocky Mountain Cancer Centers, LLP, Denver, CO; and Celgene Corporation, Overland Park, KS."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.04.117"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V110.11.817.817"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.04.044"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.12.3835"},{"key":"B5","first-page":"3671","volume":"96","author":"Cheson BD","year":"2000","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.4346"},{"key":"B7","unstructured":"Vidaza (azacitidine) package insert. 2007 Summit, NJ Celgene Corporation"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp048266"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21860"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.08.5696"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-01-068833"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa061292"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21792"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2008.26.15_suppl.7091"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-0080"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2008.17.1058","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T23:29:43Z","timestamp":1653521383000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2008.17.1058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4,10]]},"references-count":15,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2009,4,10]]}},"alternative-id":["10.1200\/JCO.2008.17.1058"],"URL":"https:\/\/doi.org\/10.1200\/jco.2008.17.1058","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,4,10]]}}}